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Osmotic drug delivery remains an area of interest for its potential in 
answering many formulation related problems. However it suffers from 
a number of drawbacks which made it difficult to fully unleash this 
concept. With the advent of new technologies like asymmetric 
membrane capsules (AMCs); new doors have got opened in this field. 
Asymmetric membrane capsules are based on the concept of osmotic 
pressure but are much simpler to manufacture. Further, they can be 
suitably optimized by varying the parameters like concentration of pore 
former, polymer, osmotic agents and solubility enhancers to cater the 
specific needs of a particular formulation. The concept can be utilized to 
deliver a number of drugs belonging to different pharmacological 
categories. However the work in this field is still in infancy. Present 
review emphasizes on the conceptual as well as formulation related 
aspects of asymmetric capsules. It also addresses the developmental 
work done in this field. 
Keywords: Controlled drug delivery, Osmosis, Asymmetric membrane, 
in situ pore formation, Phase inversion, Wet process. 
 
Introduction 
Drug dose and dosing intervals are critical in 
maintaining drug concentration within 
therapeutic window thus ensuring efficacy while 
minimizing side effects. Dosing more than once 
daily greatly reduces patient compliance. Poor 
patient compliance is the most common reason 
for failure of various therapies. This becomes 
much more crucial in case of anti-infective 
therapy and drugs for chronic use. This strictly 
demanded controlled release drug delivery 
systems.  
 
Oral controlled release (CR) systems continue to 
be the most popular amongst all drug delivery 
systems. The conventional CR systems like 
matrix or reservoir pose problems of 
bioavailability fluctuations due to variations in 
gastric pH and hydrodynamic conditions of the 
body. Osmotically controlled oral drug delivery  
 
systems utilize principles of osmosis for 
controlled delivery of drugs. These systems 
release the drugs independent of GI physiological  
factors to a large extent [1]. 
 
Alza CorporationR of USA was the first to 
develop an oral osmotic pump [2]. The simplest 
design consists of an osmotically active core 
surrounded by a semipermeable membrane, with 
one or more delivery ports through which the 
drug is delivered in a controlled fashion. Various 
modifications of this basic design have been 
reported. One such modification is the utilization 
of asymmetric membrane coating for osmotic 
drug delivery [3]. Asymmetric Membrane 
Capsules are the simplest and a promising 
osmotic system with in situ pore formation by 
avoiding laser drilling and can also be used for 
the controlled delivery of poorly soluble drugs. 





Concept of osmotic drug delivery: Osmosis 
Osmosis refers to the process of movement of 
solvent molecules from lower concentration to 
higher concentration across a semi permeable 
membrane. Osmotic Pressure created due to 
imbibitions of external environment fluid into the 
dosage form, regulates the delivery of drug from 
osmotic device. Rate of drug delivery from these 
devices is directly proportional to the osmotic 
pressure created due to imbibitions of fluids and 
hence the system releases typically by Zero order 
[4,5]. 
 
Assuming ideality, osmotic pressure is given by 
Van’t Hoff and Morse equation [6], 
π V = n RT     (1) 
n – Moles of solute 
R – Universal gas constant 
T – Temperature 
 
When the chemical potential is written in terms 
of activity 'a' of the solvent in B [5] 
π = -RT (lna)/V      (2) 
 
From monoequilibrium thermodynamics, the rate 
of water transport through the membrane can 
be written as [7] 
dv/ dt = (A/h)Lp(σΔπ - Δp)      (3) 
Dv / dt - Flow rate of solvent through the 
membrane 
A   - Cross sectional area for transport 
h   - Membrane thickness 
Lp  - Mechanical permeability of the membrane 
σ   - Reflection coefficient 
Δπ - Osmotic pressure difference across the 
membrane. 
Δp  - Hydrostatic pressure difference across the 
membrane 
 
Usually, as the size of delivery orifice increases, 
Δp << 1 
 
So, Δπ>>P 
Hence,              dv/ dt = (A/h) k Δπ (4) 
Where k = Lpσ, effective permeability of the 
Membrane 
Usually σ , the reflection coefficient of SPM is 
close to 1, in which case k~Lp [7] 
 
The rate of drug delivery (dm /dt) from the 
generic osmotic pump is given by eq. 5 [7] 
dm /dt = (dv /dt) C            (5) 
From (4), 
dm /dt = (A /h) k ΔπC          (6) 
Where, C - concentration of the drug 
 
The release rate from the oral osmotic system is 
zero order from t=0 until a time tz , at which all 
of the solid in the core has dissolved and is 
described by eq. 7 [6]: 
(dm /dt) z = (A /h) k πz S         (7) 
S – Solubility of the drug 
πz – osmotic pressure at saturation 
 
As, the rate of dissolution of a single compound 
within the system is much larger than rate of 
pumping so, C is replaced with S from t=0 to tz in 
(7). 
 
The non-zero order release rate from the time tz to 
t, when concentration changes from S to C, 
cgoverned by C as a function of time (t) 
So, (dm/dt) t = [A / h] k π ΔC(t) (8) 
 
Hence, 
From (7) & (8), factors governing release kinetics 
from oral osmotic pump: 
Solubility of the drug at saturation, S; Osmotic 
pressure difference across the semi permeable 
membrane Δπ;  Permeability of semi permeable 
membrane to water, k; Membrane thickness, h. 
 
Controlled Porosity Osmotic Pump (CPOP) 
The novel modified oral osmotic system 
maintains control over drug release by controlling 
the porosity of the membrane surrounding the 
drug core, hence the name controlled porosity 
osmotic pump. These are extension of elementary 
osmotic pumps (EOPs) with no need to create a 
delivery orifice [8,9]. The surrounding membrane 
has an asymmetric structure (fig 3) i.e, it has a 
relatively thin, dense region supported on a 
thicker, porous region. Most of the resistance to 
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mass transfer is exerted by dense portion while 
porous substrate provides mechanical strength 
and durability [8]. 
 
 
Fig- 3, Cross section of asymmetric membrane showing 
dense region supported over porous region. 
 
AMCs: Novel Approach over conventional 
osmotic systems 
Apart from possessing features of conventional 
oral osmotic systems such as independence of 
drug release from GI conditions, a high degree of 
IVIVC, higher drug release rates etc. AMCs offer 
many advance features. 
 
EOP is limited to Drugs with moderate to high 
solubilities but AMCs because of high water flux 
and permeability allows greater flexibility in 
incorporating drugs with lower solubilities and in 
designing of formulations with faster release rates 
in contrast to other oral osmotic systems [10, 11]. 
 
AMCs do not require laser drilling because of in 
situ pore formation [9,12] and are fabricated 
using conventional Pharmaceutical process 
equipments without additional manufacturing 
complexities, thus simple, economical and time 
saving [13]. Selection of two formulations being 
compressed and compression are critical factors 
in in case of push – pull and sanwitched osmotic 
tablets [14] while excipient incorporation in 
AMCs is simply mixing and filling [9]. 
 
Skin layer porosity is easily controlled with 
selection of pore former type and its 
concentration [2] and thus optimization of orifice 
size do not require mathematical calculations as 
in case of other oral osmotic systems [7]. 
The solubility modifying components and 
osmogens in the core are maintained over the 
entire drug delivery duration by encapsulating 
these in rate controlling membrane itself unlike 
other osmotic systems in which the components 
are depleted rapidly before the drug and thus 
reverting the release rates either too slow for 
poorly soluble drugs or too fast for highly soluble 
drugs [15]. Further delivery rate is almost 
independent of delivery orifice within size limits 
[16].  
 
The system requires small number and small 
quantities of excipients to be incorporated within 
the core [13]. Since a small number of capsules 
can be manually filled with test formulations and 
tested for their drug release rate, the AMCs offers 
a convenient means to screen several drug 
excipient compositions. Thus, the feasibility of 
prolonged release can be determined in a 
relatively short time with small quantities of bulk 
drug. This is a major advantage in an industrial 
setting when dealing with early drug candidates 
[8]. 
 
The capsules are made from components which 
have a long history of use as pharmaceutical 
excipients. So, test formulations made using 
AMCs can be administered to an appropriate 
animal species or humans to test the performance 
of the formulation or assess the validity of 
proposed pharmacological concepts [8]. All 
above discussed features of AMCs make them a 
promising solution to the problem existing with 
other osmotic systems. 
 
Release Mechanism of AMCs: Osmosis 
through pores formed in situ 
Drug release takes place through controlled 
porosity pores formed in situ. Once the system 
comes in contact with aqueous environment, 
water soluble additives present in the membrane 
dissolves, resulting in, in situ sponge like micro 
porous membrane of controlled porosity which is 
permeable to both water and dissolved drug 
agents and osmotic pumping system results 
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Fig 4. In Situ Pore Formation 
 
As water diffuses into the core, the volume of the 
imbibed water creates a hydrostatic pressure 
difference across the membrane, which forces the 
solution out through the pores in the coating. Here 
the volume of drug solution delivered will be 
roughly equal to the volume of water imbibed 
within a given time interval. This delivers 
constant dosage form volume [8,20]. 
 
Therefore, the rate of drug delivery will be 
constant as long as [3] osmotic pressure gradient 
across the membrane, membrane permeability 
and concentration of drug in the expelled solution 
remains constant. When the drug concentration in 
the core fluid falls below saturation, the release 
rate declines. 
 
However osmosis is not the only mechanism 
involved in the release of the drug. The capsule 
shell does not dissolve instantly to release the 
drug, instead drug is released over a prolonged 
duration by diffusion through the walls and via 
osmotic pumping through pores [8,20]. 
 
The total amount of drug delivered from AM 
dosage form per unit time, (dm / dt) t is [20]: 
 
(dm/dt) t = (dm/dt) + (dm/dt) d      (9) 
Where,  
(dm/dt) - amount released by osmotic pumping 
(dm/dt) d - amount released due to diffusion. 
 
Osmosis: 
From eq. 6        (dm/dt) = (A/h) k Δπ C 
 
Rate of drug delivery during initial portion of 
release profile is [21]: 
(dm/dt) = (A/h) k Δπ S      (10) 
Where, S – concentration of drug in the fluid 
being pumped out If AM capsule contains only 
one component, the Δπ is caused by a saturated 
solution of drug one one side of the capsule wall 
and sink conditions outside the wall. Assuming 
ideality, Δπ is [21]: 
 
From eq. 1 Δπ = (n/V) RT = (S/M) RT      (11) 
Where, M – molecular weight of the drug 
 
Sudstituting expression of Δπ into Eq. 10 
(dm/dt) = (A/h) k RTP S2/M       (12) 
 
Eq. (12) indicates that a plot of the release rate 
versus (S2/M) should be linear with a slope given 
by the expression in parentheses [21]. 
 
Diffusion[20]: 
The diffusional contribution is derived from the 
fact that the asymmetric membrane is not 
perfectly semipermeable, and therefore a portion 
of drug is released by diffusion, primarily 
through pores in the coating 
(dm/dt) d = (Pd AS)/h     (13) 
Where, Pd - dissolved drug permeability in the 
membrane 
Combining eq. 9, 10 and 13, the total drug release 
is described by: 
(dm/dt)t = (A/h) k Δπ S + (Pd AS)/h       (14) 
 
Components of AMCs 
Asymmetric Membrane 
Ideal properties: 
Stable to outer and inner environment, 
biocompatible, sufficiently rigid and semi 
permeable. Membrane must have sufficient water 
permeability so as to provide high water fluxes 
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It should have sufficient wet strength (~105 psi) 
and wet modulus (~105 psi) so as to retain its 
dimensional integrity during operational lifetime 
of the device. The reflection coefficient, 
“leakiness“of the membrane to osmotic agent 
should approach to limiting value of 1[6,30]. 
 
It should have sufficient thickness, as per eq. 14 
membrane thickness has an inverse effect on 
release a, compromise should be made for 
"thickness" as thinner membranes shows an 
increase in  the release but do not withstand the 
pressure within the device, a thicker membrane 
although is able to resist the pressure but shows a 
constrained release because of increased 
diffusional path for the drug to traverse before 
being released [23,24]. 
 
Composition: 
Water insoluble Polymer [8,25]: The thickness 
of the membrane is controlled by the film 
forming polymeric materials and consists of: 
Cellulose derivatives such as Cellulose Acetate 
(CA), Ethyl Cellulose (EC), Cellulose Acetate 
Butyrate (CAB) etc. A mixture of polymers can 
also be used . 
 
Channeling Agents: They are non-solvents or 
poor solvents for the film forming polymer but 
are water soluble, are employed to control the 
porosity of the membrane. [17]. Examples 
include: Glycerol, sorbitol, glycols like 
polyethylene glycol (PEG), dimetylsulfone, 
organic aliphatic and aromatic acids, dibutyl 
phthalate (DBT), erodilble materials, such as 
poly(glycolic), poly(lactic) acid and many others 
[8,25]. 
 
Solvent system: It consists of solvent-cosolvent 
system. These are usually mixtures of: 
acetoneethanol, acetone-water, acetone-isopropyl 
alcohol, acetone-butyl alcohol [8].  
 
Core Formualtion: 
Drug- Criteria for selection: The drug either 
should have a short biological half life, potent or 
required for prolonged release [4]. Also it should 
not have either very high or very low solubility. 
Assuming the capsule formulation to consist only 
of pure drug, the fraction of the drug released 
with zero order kinetics is given by eq.15 [26,27]: 
F(Z) = 1- S/ρ       (15) 
Where, F(Z) = fraction of drug released by zero 
order kinetics 
S = solubility of the drug (g/cm3) 
ρ = density of the drug (g/cm3) 
 
Osmogen: Apart from having high aqueous 
solubility a suitable osmogen should provide a 
pH environment where drug solublizes[15]. 
 
Eq. 7 describes the direct relationship between 
the osmotic pressure and the amount of drug 
released. Drugs with a solubility of 0.05 g/cm3 
would be released with 95% zero-order kinetics 
according to Eq15. However, zero order release 
rate would be slow because of the small osmotic 
pressure gradient. Hence an additional osmotic 
agent must be added to the core formulation [26]. 
These include sugars such as sucrose, mannitol; 
inorganic water soluble salts such as sodium 
chloride, potassium chloride; water soluble acids, 
alcohols, surfactants such as sodim lauryl 
sulphate (SLS); organic polymers such as 
hydroxylpropylmethyl cellulose (HPMC) , 
sodium carboxymetyl cellulose (NaCMC) etc 
[4,25]. 
 
Solubility Modifying Agents: 
Solublizers 
Osmogens like sugars have effect only on 
osmotic pressure without affecting solubility of 
the poorly water soluble drug, thus exhibiting 
poor release. Such formulation necessitates 
incorporation of a solublizer for the drug along 
with osmogen [15]. 
 
These agents provide a pH environment in which 
drug has a high solubility [28]. These include 
tartaric acid, citric acid, sorbic acid, fumaric acid, 
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Solubility Dampners 
According to Eq. 17, highly water soluble drugs 
would demonstrate a high release rate that would 
be zero order for only a small percentage of the 
initial drug load thus necessitating decrease in 
solubility. A solubility suppressant can be 
incorporated in the core to deliver such drugs 
[27]. 
 
Concept of Fabrication 
Phase inversion 
The process in which the polymer solution is 
induced to undergo phase separation in a 
particular way, resulting in a structured, 
continous polymer phase. The process can be a 
wet process or dry process [25]. 
 
Wet process: It is the preferred process in which 
the coating solution, a multi- component 
polymer-solvent-nonsolvent (pore former) is 
precipitated on stainless steel mold pins 
dimensioned to form capsule body and cap 
followed by quenching in an quench bath 
consisting of a solvent in which polymer is not 
soluble but original polymer solvent system is 
soluble. The quench bath extracts the solvent (s) 
from the coated film, resulting in precipitation of 
the polymer in the form of a structured membrane 
on the mold pins [25]. The shells are removed 
from quench bath after 15 min, dried, stripped 
and trimmed. The ratio of solvents/non solvents 
is so selected that on evaporation phase inversion 
was immediately started [8]. The process is 
depicted in fig (5) 
 
Dry Process: It also utilizes the same coating 
solution precipitation as in wet process but here 
the solvent is allowed to evaporate completely. It 
requires that solvent(s) evaporate more rapidly 
than pore former [25]. 
 
After filling the body of the capsule, manually 
with core contents, cap is placed over and finally 
sealed with a sealing solution consisting of 
polymeric solution without pore former.[8] 
 
Asymmetric Membrane Capsules: Application 
and execution 
AMCs provide a sustained oral osmotic drug 
delivery system for the drugs with poor and high 
water solubilities , unaffected from gastric pH, 
hydrodynamic conditions of GIT and thus 
eradicating bioavailability fluctuations. 
Therefore, the major areas of application of 
AMCs are antibiotics, NSAIDs, 
antihypertensives, antituberculars, drugs to treat 
cardiac disorders, H2 receptor antagonists. 
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Faliure of chemotherapy of tuberculosis occurs 
due to multi-drug regimens given over long 
period of time and development of multi-drug 
resistance. D. Prabhakaran et al [2004] developed 
modified AMCs of CA with 20% glycerol for 
sustained simultaneous administration of 
Rifampicin (RI) and Isoniazid (IS) by filling RI 
in upper part and IS mixed with HPMC in lower 
part [29]. 
 
NSAIDs play a major role in the management of 
pain and various inflammatory conditions, but 
these are associated with short half life, multiple 
dosing and GI side effects. AMCs of EC were 
developed by Anil K. Philip et al. [2006] for 
sustained delivery Flurbiprofen [30] with addition 
of mannitol and citric acid in the core. 
 
Further AMCs of EC via dry process were 
developed by Anil K. Philip et al. [2007] for 
controlled delivery of Ketoprofen [31] (KT) with 
addition of NaCl in the core, and via wet process 
for controlled delivery of Flurbiprofen [32] (FL) 
[2008]. Acute toxicity studies and 
histomorphological analysis were conducted in 
rats and established the use of AMCs as a means 
for delivery of GI irritant drugs in a controlled 
through fickian diffusion. 
 
Further the same developed AMCs of the two 
NSAIDs, KT [33] and FL [24] as per 
formulations described in investigations, [2007, 
2008] and carried out in vivo studies in rabbits to 
establish level A, IVIVC with 32.94% and 
42.84% relative bioavailability compared to 
immediate release tablets of KT and FL 
respectively.  
 
First generation Cephalosporins, particularly 
Cefadroxil has poor aqueous solubility and short 
t1/2, requires multiple dosing and shows erratic 
dissolution profile in gastric fluid resulting in 
poor absorption and GI side effects. Anil K. 
Philip et al [2008] developed AMCs of CAP 
coated over CA shells for sustained delivery of 
cefadroxil [34] with addition of mannitol in the 
core, thus reducing GI disturbances and 
increasing absorption.  
 
Drugs to treat cardiac disorders need prolonged 
administration. Guarve et al. [2009] developed 
AMCs of CA for the sustained delivery of poorly 
water soluble drug Carvedilol [35] with addition 
of mannitol alone, mannitol with SLS, thus 
preventing its first pass metabolism, increasing 
absolute oral bioavailability and improved 
compliance. Further in 2010 he developed AMCs 
for extended delivery of Carvedilol [10] with 
addition of fructose and fumaric acid in the core.  
 
H2 antagonists used for the treatment of GI ulcers 
or gastro-oesophageal reflux disease should have 
gastro retentive properties. Jin Guan et al. [2010] 
developed gastro-retentive AMCs 11 of CA with 
glycerin: diethyl phthalate ratio (5:4) for 
controlled and sustained delivery of Famotidine 
[36] by addition of WSR N-80 in the core for 
floating purposes. In-vivo studies in beagle dogs 
confirmed the mechanism and showed relative 




Drug delivery using principles of osmotic 
pressure is a versatile technology and AMCs 
further extends the scope. AMCs can be used for 
controlled delivery of both highly and poorly 
water soluble drugs by modulating the core 
formulation. With ease of release programming 
by modulation of porosity, thickness and core 
formulation the system has a promising future. 
The release is driven by osmotic pressure across 
in situ pores along with a contribution from 
diffusion. Fabrication is simple and economical 
with underlying mechanism of phase inversion. 
These hold a great prospective in delivering 
various types of drugs with varying solubilities 
which includes NSAIDs, antibiotics, 
antituberculars, antihypertensives, antidiabetics, 
drugs to treat GI disorders, analgesics, GI irritant 
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technology strongly advocate its good future in 
oral controlled drug delivery. 
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